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11β-Hydroxysteroid
Dehydrogenase Type 1(11β-HSD1)
mediates insulin resistance through
JNK activation in adipocytes
Kesong Peng1,2, Yong Pan1, Jieli Li1, Zia Khan3, Mendi Fan2, Haimin Yin1,2, Chao Tong1,
Yunjie Zhao1, Guang Liang1 & Chao Zheng1,2
Glucocorticoids are used to treat a number of human diseases but often lead to insulin resistance and
metabolic syndrome. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a key enzyme that
catalyzes the intracellular conversion of cortisone to physiologically active cortisol. Despite the known
role of 11β-HSD1 and active glucocorticoid in causing insulin resistance, the molecular mechanisms by
which insulin resistance is induced remain elusive. The aim of this study is to identify these mechanisms
in high fat diet (HFD) experimental models. Mice on a HFD were treated with 11β-HSD1 inhibitor
as well as a JNK inhibitor. We then treated 3T3-L1-derived adipocytes with prednisone, a synthetic
glucocorticoid, and cells with 11β-HSD1 overexpression to study insulin resistance. Our results show
that 11β-HSD1 and JNK inhibition mitigated insulin resistance in HFD mice. Prednisone stimulation
or overexpression of 11β-HSD1 also caused JNK activation in cultured adipocytes. Inhibition of
11β-HSD1 blocked the activation of JNK in adipose tissue of HFD mice as well as in cultured adipocytes.
Furthermore, prednisone significantly impaired the insulin signaling pathway, and these effects
were reversed by 11β-HSD1 and JNK inhibition. Our study demonstrates that glucocorticoid-induced
insulin resistance was dependent on 11β-HSD1, resulting in the critical activation of JNK signaling in
adipocytes.
Glucocorticoids are steroid hormones that bind to the glucocorticoid receptor (GR) and have powerful
anti-inflammatory and immunosuppressive effects. However, patients treated with glucocorticoids develop obesity, insulin resistance, glucose intolerance, and dyslipidemia1. Currently, more than 2.5 million people in the
United States are exposed to long-term glucocorticoids2. As such, insulin resistance resulting from glucocorticoid
exposure is becoming an important public health problem and there is an urgent need to understand the mechanisms by which glucocorticoids induce insulin resistance.
Tissue-specific metabolism of glucocorticoids is catalyzed by two enzymes, 11β-hydroxysteroid dehydrogenases type 1 (11β-HSD1) and type 2 (11β-HSD2). These enzymes carry out the interconversion of non-receptor
binding cortisone and the receptor binding active form, cortisol. 11β-HSD1 is an NADP(H)-dependent enzyme
and converts inactive cortisone to active cortisol in the liver, adipose tissue, vasculature, and brain3–5. 11β-HSD2,
on the other hand, is an NAD-dependent dehydrogenase and inactivates cortisol to cortisone in the kidney and
colon6. The role of 11β-HSD1 in obesity and metabolic disease is well established in rodents. Transgenic mice
with overexpression of 11β-HSD1 driven by the adipose tissue-specific aP2 promoter express elevated corticosterone levels in adipose tissue and display a phenotype mimicking human metabolic syndrome characterized
by visceral obesity, insulin resistance, and hyperlipidemia7,8. Furthermore, administration of glucocorticoids in
mice induces metabolic syndrome, which is prevented in 11β-HSD1 knockout mice9. These findings together
with tissue-specific expression/activity of 11β-HSD1 suggest that intracellular metabolism of glucocorticoids
by 11β-HSD1 is critical to the development of insulin resistance rather than the circulating glucocorticoids.
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Therefore, 11β-HSD1 is an important therapeutic target for reducing adverse effects of prescribed glucocorticoids for treatment of a variety of diseases
The mechanism by which increased levels of 11β-HSD1 results in insulin resistance is not fully known. The
overexpression of 11β-HSD1 gene in adipose tissue can increase levels of leptin, resistin, tumor necrosis factor-α
(TNF-α), and interleukin-6 (IL-6)10,11. This suggests that high local levels of glucocorticoids, at least in adipocytes, promote an inflammatory rather than the expected anti-inflammatory activity through cortisol. This
inflammatory function of glucocorticoids may be regulated through c-Jun N-terminal kinases (JNK), which is
believed to be a central player in the insulin signaling in diabetes and insulin resistance. Reports show that JNK
knockout mice are protected against the development of insulin resistance12,13. Moreover, administration of small
molecule or peptide inhibitors of JNK significantly improved insulin sensitivity in insulin-resistant rodents14,15.
Multiple factors can activate JNK, such as inflammatory cytokines and free fatty acids. Importantly, glucocorticoids can also increase JNK activity in epithelial cells16, hippocampal cells17 and endothelial cells18. Therefore,
we hypothesized that glucocorticoid-induced insulin resistance is dependent on 11β-HSD1, resulting in critical
activation of JNK in adipose tissue. For study, we used the high fat diet (HFD) mouse model and cultured adipocytes to investigate this potential pathophysiological mechanism under conditions of obesity. Results indicate
that glucocorticoid-induced insulin resistance was dependent on 11β-HSD1, resulting in the critical activation
of JNK signaling in adipocytes.

Results

Inhibition of 11β-HSD1 and JNK improved insulin sensitivity. Specific small-molecule inhibitors
of 11β-HSD1 and JNK (PF0091527519 and C6620, respectively) were used to investigate the causal mechanism
between glucocorticoid excess and development of insulin resistance. Our results show that mice fed with
HFD have significantly increased body weights compared to the mice fed standard chow (Fig. 1a). Treatment
of HFD mice with PF00915275 reduced weight gain compared to the mice treated with vehicle after 8 weeks
(39.87 ± 4.60 g vs 44.77 ± 6.78 g, Fig. 1a). As expected, blood glucose levels and glucose AUC were significantly
increased in HFD mice (Fig. 1b,c). Administration with either PF00915275 or C66 significantly decreased
blood glucose AUC in HFD mice compared to vehicle treatment (Fig. 1b,c). The effects of HFD on expression of
11 β-HSD1 and glucocorticoid receptor (GR) proteins in mice were next investigated. Western blot analysis
showed that HFD significantly increased the expression of both 11 β-HSD1 and GR in subcutaneous adipose tissues (Fig. 1d). We also assessed the adipose tissue of PF00915275- and C66-treated mice for expression of insulin
receptor substrate 1 (IRS1), glucose transporter-4 (GLUT4), adiponectin and fatty acid binding protein (FABP)
as indices of insulin sensitivity. The mRNA levels of IRS-1 (Fig. 1e), GLUT4 (Fig. 1f) and adiponectin (Fig. 1g)
were decreased in the adipose tissue of HFD mice, whereas treatment with PF00915275 and C66 prevented their
decreased expression and thereby preserved insulin sensitivity (Fig. 1e–g). In addition, HFD upregulated the
expression of FABP in subcutaneous adipose tissue which was completely abolished by PF00915275 and C66
(Fig. 1h). These data confirmed that inhibition of either 11β-HSD1 or JNK significantly attenuated the HFDinduced insulin resistance in mouse adipose tissues.
We also determined JNK activaton by measuring its phosphorylation in the mouse adipose tissues. JNK phosphorylation was significantly increased in the adipose tissue of HFD mice, which was blocked by the administration of the JNK inhibitor C66 (Fig. 1i). Importantly, treatment of the mice with the 11β-HSD1 inhibitor
PF00915275 also attenuated HFD-induced JNK phosphorylation (Fig. 1a). These findings support the idea that
11β-HSD1 is an upstream regulator of JNK in modulation of insulin resistance in the HFD model.
11β-HSD1 is an upstream regulator of JNK activation. We further investigated the regulation of JNK
by 11β-HSD1 using cultured adipocytes differentiated from 3T3-L1 cells. Treatment of adipocytes with prednisone (a synthetic glucocorticoid) resulted in increased expression of 11β-HSD1 (Fig. 2a) and GR (Fig. 2b).
This increase was blocked with pretreatment of cells with 11β-HSD1 inhibitor PF00915275. As expected from
our in vivo studies, treatment of 3T3-L1 pre-adipocytes with prednisone increased phosphorylation of JNK and
this increase was abolished by PF00915275 and C66 (Fig. 2c). The findings indicated that prednisone activated a
sequential pathway of increased 11β-HSD1 expression/activity and JNK activity.
We further investigated the effects of 11β-HSD1 overexpression in pre-adipocyte 3T3-L1 cells on JNK activation. Overexpression of 11β-HSD1 significantly increased JNK phosphorylation which was blocked by C66
(Fig. 2d). It is well established that TNF-αcan activate JNK and induce insulin resistance. To test whether there
are additive effects of TNF-αand 11β-HSD on JNK phosphorylation, we treated 11β-HSD1-overexpressing cells
with TNF-α. Both TNF-αand overexpression of 11β-HSD increased JNK phosphorylation. The combination of
TNF-αand overexpression of 11β-HSD further elevated the level of p-JNK (Fig. 2e). However, neither JNK activator TNF-αnor JNK inhibitor C66 altered the expression level of 11β-HSD1 and GR (Fig. 2f–i). Overall, these
findings indicate that JNK is downstream of 11β-HSD1 in the regulation of insulin resistance.
JNK inhibition by C66 attenuated prednisone- and 11β-HSD overexpression-induced insulin
resistance. Our findings showed that the prednisone-11β-HSD1 pathway resulted in JNK activation in

3T3-L1 cells. To evaluate the significance of this JNK activation pathway in development of insulin resistance, we
determined the effects of C66 on prednisone-induced insulin resistance. Treatment of 3T3-L1-derived adipocytes
with prednisone decreased insulin-stimulated glucose uptake (Fig. 3a), phosphorylation of Akt (Fig. 3b), and the
expression of IRS-1 (Fig. 3c), GLUT4 (Fig. 3d), and adiponectin (Fig. 3e). Moreover, prednisone also increased
FABP mRNA expression (Fig. 3f). The pretreatment with JNK inhibitor C66 or 11β-HSD1 inhibitor PF00915275
significantly reversed these prednisone-induced indices of insulin resistance (Fig. 3a–f). Western blot analysis for
p-IRS1Ser302 and IRS1 confirmed the inhibition by C66 and PF00915275 on prednisone-induced insulin resistance
in 3T3-L1 cells (Fig. 3g). Consistently, the overexpression of 11β-HSD1 also decreased insulin-stimulated glucose
Scientific Reports | 6:37160 | DOI: 10.1038/srep37160
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Figure 1. Treatment with PF00915275 and C66 inhibited insulin resistance in high-fat fed mice.
PF00915275 (5 mg/kg) and C66 (5 mg/kg) were administered orally once every other day for 8 weeks to high
fat diet-fed mice. (a) Body weight of HFD mice with or without PF00915275 or C66 treatment for 8 weeks
showing that PF00915275 treatment reduced weight gain in mice fed HFD. (b) OGTT were performed on
mice following the completion of all treatments and just before sacrifice. (c) Blood glucose AUC was calculated
based on OGTT data presented in B. (d) protein levels of 11β-HSD1 and GR in subcutaneous adipose tissues
from mice fed with normal chow or HFD was determined by western blot analysis. The gels were run under
the same experimental conditions. Shown are cropped gels/blots (The gels/blots with indicated cropping lines
are shown in Supplementary Fig. S1). Representative two mouse tissues from n = 8 were shown. (e–i) mRNA
quantification of IRS-1 (e) GLUT (f) adiponectin (g) and FABP (h) by qPCR. (i) Akt phosphorylation levels
measured in the adipose tissues. The gels were run under the same experimental conditions. Shown are cropped
gels/blots (The gels/blots with indicated cropping lines are shown in Supplementary Fig. S1). Data was presented
as mean ±  S.E.M. *P <  0.05; **P <  0.01, ***P < 0.001 compared with the vehicle-treated group. n = 8 per group.

uptake in 3T3-L1 cells, which was reversed by JNK inhibitor C66 pretreatment (Fig. 3h). Insulin increased Akt
phosphorylation in control 3T3-L1 cells but not in11β-HSD1-overexpressing cells (Fig. 3i). Furthermore, pretreatment with JNK inhibitor C66 significantly reversed Akt inhibition caused by 11β-HSD1 overexpression
(Fig. 3i).

Inactivation of JNK by DN-JNK prevented the 11β-HSD1-dependent insulin resistance.

To
exclude possibility of any nonspecific action of C66, we generated 3T3-L1 cells expressing dominant-negative
JNK (DN-JNK). As shown in Fig. 4a, transfection of DN-JNK plasmid in 11β-HSD1 overexpressing cells blocked
the phosphorylation of JNK. DN-JNK also improved TNF-α- and 11β-HSD1 overexpression-induced glucose
uptake (Fig. 4b,d), and insulin-induced Akt phosphorylation (Fig. 4c). Furthermore, TNF-αco-incubation with
insulin inhibited insulin-induced Akt phosphorylation and this, as well, was reversed in DN-JNK-transfected
cells (Fig. 4c). Lastly, we tested the effects of DN-JNK on insulin resistance induced by 11β-HSD1 overexpression. 11β-HSD1 overexpression significantly decreased insulin-induced glucose uptake (Fig. 4d) and Akt
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Figure 2. Inhibition of 11β-HSD1 reduced JNK activation in 3T3-L1 cells. (a,b) 3T3-L1 cells were
pretreated with PF00915275 (10 μM) or vehicle (DMSO) for 2 h and then incubated with prednisone (5 μM)
or DMSO for 1 h. Cell lysates were collected and 11β-HSD1 (a) and GR (b) were detected by western blotting.
(c) Western blot analysis of JNK phosphorylation in adipocytes. Cells were treated as in A and B. (d) Cells
with 11β-HSD1 overexpression were incubated with C66 (10 μM) or DMSO for 2 h. The expression of p-JNK/
JNK was determined by western blot analysis. (e–g) Cells with 11β-HSD1 overexpression were incubated with
TNF-α (1 μg/mL) or vehicle for 1 h. Cell lysates were collected and p-JNK/JNK (e), 11β-HSD1 (f) and GR (g)
were detected by western blotting. (h,i) 11β-HSD1 overexpressig cells were incubated with C66 (10 μM) or
DMSO for 2 h. The expression of 11β-HSD1 (h) and GR (i) was assayed. All the gels were run under the same
experimental conditions. Shown are cropped gels/blots (The gels/blots with indicated cropping lines are shown
in Supplementary Fig. S1). *P <  0.05, **P <  0.01, ***P < 0.001, all data from 3 independent experiments.

phosphorylation (Fig. 4e) in 3T3-L1 cells. As expected, blocking JNK activation by DN-JNK improved glucose
update (Fig. 4d) and increased AKT phosphorylation (Fig. 4e).

Discussion

The main finding of our study is that glucocorticoid-induced insulin resistance was dependent on 11β-HSD1,
leading to JNK activation. Administration of glucocorticoids or overexpression of 11β-HSD1 in adipocytes
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Figure 3. JNK inhibition by C66 attenuated insulin resistance induced by prednisone or 11β-HSD1
overexpression in adipocytes. (a) 3T3-L1 cells differentiated into adipocytes and then treated with PF00915275
(10 μM), C66 (10 μM) or vehicle (DMSO) for 2 h followed by incubation with prednisone (5 μM) or DMSO
for 6 h. Glucose uptake rate was measured as described in the methods section. (b) Cells were treated with
PF00915275 (10 μM), C66 (10 μM) or vehicle (DMSO) for 2 h and then with prednisone (5 μM) or DMSO
for 2 h. p-Akt/Akt proteins levels were then determined by western blotting. The gels were run under the
same experimental conditions. Shown are cropped gels/blots (The gels/blots with indicated cropping lines
are shown in Supplementary Fig. S1). (c–f) Cells were treated as in A and mRNA levels of IRS-1 (c), GLUT4
(d), Adiponectin (e) and FABP (f) were examined by qPCR. (g) Cells were treated as in B and protein levels of
p-IRS1Ser302 and IRS1 were examined by western blot analysis. The gels were run under the same experimental
conditions. Shown are cropped gels/blots (The gels/blots with indicated cropping lines are shown in
Supplementary Fig. S1). Representative blots from 3 independent experiments were shown. (h,i): Differentiated
3T3-L1 cells with or without 11β-HSD1 overexpression were treated with C66 (10 μM) or vehicle (DMSO) for
2 h and then incubated with insulin (100 nM) for 15 min. Glucose uptake rate (h) and Akt phosphorylation
(i) were determined. The gels were run under the same experimental conditions. Shown are cropped gels/
blots (The gels/blots with indicated cropping lines are shown in Supplementary Fig. S1). *P <  0.05, **P <  0.01,
***P < 0.001; all data from 3 independent experiments.
increased JNK phosphorylation and induced features of insulin resistance, which were blocked by inhibiting
11β-HSD1 or JNK.
Glucocorticoids are widely used in the clinic as anti-inflammatory agents for a number of human diseases
including autoimmune diseases, cancer, organ rejection, and asthma. However, glucocorticoids often lead to insulin resistance and diabetes, a condition referred to as steroid-induced diabetes. A number of studies have shown
Scientific Reports | 6:37160 | DOI: 10.1038/srep37160
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Figure 4. Inactivation of JNK relieved insulin resistance induced by 11β-HSD1 overexpression.
(a) 3T3-L1 cells with or without 11β-HSD1 overexpression were transfected with DN-JNK or control plasmid
and expression of p-JNK/JNK was assayed. The gels were run under the same experimental conditions. Shown
are cropped gels/blots (The gels/blots with indicated cropping lines are shown in Supplementary Fig. S1).
(b) Differentiated 3T3-L1 cells were transfected with DN-JNK or control plasmid and then incubated with
TNF-α (1 μg/mL) for 6 h. Following TNF-αtreatment, glucose uptake rate was detected. (c) Cells expressing
DN-JNK were treated with TNF-α (1 μg/mL) for 15 min to assess the level of p-Akt/Akt. (d) 11β-HSD1
overexpressing cells were transfected with DN-JNK and incubated with insulin (100 nM) for 15 min. Following
insulin treatment, glucose uptake rate was calculated. (e) Level of p-Akt/Akt in cells treated as in D. The gels
from Fig. 4C and Fig. 4E were run under the same experimental conditions, respectively. Shown are cropped
gels/blots (The gels/blots with indicated cropping lines are shown in Supplementary Fig. S1). *P <  0.05,
**P <  0.01, ***P < 0.001; all data from 3 independent experiments.

that the local/intracellular production of glucocorticoids by 11β-HSD1 is more critical than the circulating pool
for the development of insulin resistance9. Over-expression of 11β-HSD1 in the mouse liver causes active glucocorticoid excess and induces metabolic disorders, while 11β-HSD1 knockout mice are resistant to HFD-induced
insulin resistance and metabolic syndromes21–23. Thus, 11β-HSD1 is believed to an important target for the treatment of type 2 diabetes and metabolic syndromes. However, despite the well-documented role of 11β-HSD1 and
active glucocorticoids in causing insulin resistance, the underlying molecular and cellular mechanisms remain
unknown. Recent studies showed cross-talk between 11β-HSD1 and JNK, for example, that JNK activation was
involved in IL-3-induced 11β-HSD1 expression in airway smooth muscle cells24, and inhibition of 11β-HSD1
mediated TNF-α-induced JNK activation and inflammation in pre-adipocytes25. However, our studies have
demonstrated, for the first time to our knowledge, that JNK plays a central role in the insulin resistance induced
by exogenous glucocorticoids or 11β-HSD1 activation (Fig. 5).
Adipose tissue plays an essential role in regulation of whole-body insulin sensitivity. And glucocorticoids
have profound effects on the adipose tissue, such as driving central obesity by promoting the redistribution
of fat from periphery to abdomen and inducing pre-adipocyte differentiation26,27. Interestingly, 11β-HSD1 is
highly expressed in adipose tissues28. Based on the important role of 11β-HSD1 in adipose tissue and insulin
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Figure 5. Working model depicting the underlying mechanism of 11β-HSD1- mediated insulin resistance.
Glucocorticoids (inactive) cause activation of 11β-HSD1 in adipocytes producing active glucocorticoids.
Active glucocorticoid-GR signaling complex activates the JNK pathway. JNK then inhibits insulin-induced
Akt phosphorylation leading to insulin resistance. JNK may also be activated by inflammatory cytokines such
as Tumor necrosis factor-α. [GCs =  glucocorticoids, GR = glucocorticoid receptor, IR =  insulin receptor,
JNK = c-Jun N-terminal kinase; site of action of various inhibitors is also shown (green text)].

resistance, we explored the 11β-HSD1-JNK pathway in regulation of insulin resistance. We found that inhibition
of 11β-HSD1 or JNK was protective against development of insulin resistance in the HFD mouse model. A recent
study has also shown that corticosterone treatment of adipocytes enhances 11β-HSD1 expression and impaired
p-Akt leading to lipolysis. Furthermore, knockdown of 11β-HSD1 by shRNA attenuated corticosterone-induced
lipolysis and improved insulin signaling response in adipocytes29. Taken together, these findings suggest that
glucocorticoid signaling in adipocytes leads to an 11β-HSD1-dependent impairment of insulin.
A potential limitation of our study is that we did not examine the liver tissues in these mice. Insulin and
11β-HSD1 also function in the liver. However, the mechanisms may be shared with adipocytes and may also
involve JNK. Whole body knockout of JNK or JNK inhibitor dramatically improved insulin sensitivity 12.
Interestingly, specific suppression of JNK activation in adipose tissue alone is sufficient to prevent the development of insulin resistance in HFD mice30. JNK interferes with insulin signaling through several mechanisms.
JNK inhibits IRS1 function through phosphorylation of IRS1 at Ser307 31 or downregulation of IRS1 expression32.
JNK activation in adipose tissue has also been shown to decrease the production of adiponectin, which contributes to insulin resistance induced by JNK activation30,33. Furthermore, FABP is essential for adipocytes to
produce TNF-α. Mice with FABP deletion are resistant to HFD-induced metabolic abnormality34. However, an
independent group found that lipopolysaccharide induces FABP upregulation through activation of JNK35. Thus,
FABP may also be implicated in JNK-induced insulin resistance. Our studies showed that glucocorticoid treatment or overexpression of 11β-HSD1 decreased IRS1 and adiponectin expression and increased FABP activation.
These insulin resistance-related changes were reversed by JNK inhibition, establishing the importance of the
glucocorticoid-11β-HSD1 pathway in JNK activation.
Activation of JNK by glucocorticoids and its involvement in insulin signaling has been also reported by other
groups in different systems. For example, heat shock (DNAJB3) proteins have been shown to improve insulin
signaling and glucose uptake through JNK repression36. Pigment epithelium-derived factor (PEDF) also suppresses JNK activation to improve hepatocyte insulin signaling37. We found that glucocorticoids activated JNK
in adipocytes, resulting in aberrations in the insulin signaling pathway. Despite our findings and those by others, the specific molecular mechanisms by which the GC-GR complex activates JNK remain elusive. A previous study has demonstrated that GR could physically bind to JNK in dexamethasone-treated HeLa cells38. Our
co-immunoprecipitation studies found that treatment with 5 μM prednisone for 2 h induced formation of the
GR-JNK complex in 3T3-L1 adipocytes (Supplementary Figure S2), which confirmed the previous results38.
However, the co-immunoprecipitation data could not rule out the existence of other linker proteins in the complex. In addition, multiple lines of evidence have shown that glucocorticoids can directly activate protein kinase
C (PKC) isoforms17,39–43 which are upstream activators of JNK44–47. PKC activation has also been demonstrated to
cause insulin resistance48–50. Thus, PKCs may contribute to the activation of JNK in response to glucocorticoids
in adipocytes. hese observations suggest other additional mechanisms can be involved. Overall, findings from
our study strongly support a role of JNK activation in GC-induced insulin resistance. An important direction for
future studies is to elucidate the mechanisms by which GC/GR activate JNK.
In conclusion, our study identified a novel mechanism by which a glucocorticoid-11β-HSD1 pathway induced
insulin resistance through JNK activation in adipocytes Moreover, the results suggest that 11β-HSD1 and its
downstream target molecule, JNK, are key therapeutic strategies for treating insulin resistance in response to
glucocorticoid excess.
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Materials and Methods

Materials. Prednisone, 11β-HSD1 inhibitor PF-0091527519, TNF-α, and insulin were purchased from Sigma-

Aldrich (St. Louis, MO). Compound C66, a JNK inhibitor, was synthesized and purified (>98.4%) as described in
our previous studies51–53. PF00915275 and C66 were dissolved in DMSO for in vitro experiments and in CMC-Na
(1%) for in vivo experiments. A 3.3-kb cDNA fragment encoding dominant negative JNK fusion protein and
vector cDNA (control) were a kind gift from Professor Aimin Xu (School of Medicine, University of Hong Kong,
Hong Kong)20. Antibodies for 11β-HSD1, GR, phospho-JNK (p-JNK), JNK, phospho-Akt (Thr308) (p-Akt), Akt
and GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The glucose concentration assay
kit was purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China).

Cell culture. The mouse pre-adipocyte line 3T3-L1 was obtained from the Shanghai Institute of Biochemistry
and Cell Biology (Shanghai, China). Cells were cultured in Dulbecco’s modified Eagle medium (DMEM) medium
(Gibco, Thermo Fisher) containing 25 mM D-glucose supplemented with 10% fetal bovine serum, 100 U/mL
penicillin and 100 mg/mL streptomycin at 37 °C in a humidified 5% CO2 atmosphere. Upon confluence, cells
were trypsinized and plated onto culture dishes for the measurement of kinase phosphorylation, and protein
expression and mRNA levels. Prednisone was incubated for the indicated time intervals. For some experiments,
cells were pre-treated with inhibitors for 2 h before prednisone treatment.
3T3-L1 cells differentiation. To induce the differentiation of 3T3-L1 cells into adipocytes, cells were cultured to confluence. Cells were then treated with complete differentiation medium which contained 10 mg/L
insulin, 1 μM dexamethasone and 0.5 mM IBMX (isobutyl-methylxanthine). Medium was changed after 2 days
with fresh medium containing 10 μg/L insulin, then every other day for a total of 10 days. On day 11, cells were
cultured in serum-free medium for 24 h and then treated with prednisone or TNF-αfor 6 h to induce insulin
resistance.
Adipocyte glucose uptake.

The amount of glucose taken up by the differentiated 3T3-L1 adipocytes cells
was measured by determining the difference of glucose concentrations in the culture medium before and after
incubation with cells. Glucose levels in the medium were measured using a glucose assay kit. The results were
expressed as glucose uptake rate compared to the insulin-treated group (100%).

Cell transfections.

3T3-L1 cells were transfected with the plasmid, pLV.EX3d.P/neo-EF1A >  HSD11B1 > 
IRES/eGFP, to overexpress 11β-HSD1 or control plasmid using lipofectamine 2000. Cell lines were established by
culturing cells in selection media with 500 μg/mLof G418.
For dominant negative JNK (DN-JNK) transfections, cells were incubated for 6 h in 1 mL serum-free medium
containing 10 μL Lipofectamine 2000 and 2.5 μg DN-JNK or empty vector plasmid. Forty eight hours after transfection, cells were treated with 1 μg/mL TNF-αor vehicle control for 1 h.

Animals.

Six week old male C57BL/6 mice weighing 18–22 g were obtained from the Animal Centre of
Wenzhou Medical University (Wenzhou, China). Animals were housed with a 12:12 h light–dark cycle at constant room temperature, and fed standard chow diet. The mice were acclimatized to the laboratory for at least
2 weeks before initiating studies. All animal care and experimental procedures were approved by the Wenzhou
Medical University Animal Policy and Welfare Committee and performed in accordance with the approved
protocols and the “The Detailed Rules and Regulations of Medical Animal Experiments Administration and
Implementation”(Document No. 1998-55, Ministry of Public Health, China).
Control mice (n = 8) were fed with standard chow diet (low fat diet) which contained 10 kcal.% fat, 20 kcal.%
protein and 70 kcal.% carbohydrate (MediScience Diets Co., Yangzhou, Chinca; Cat. #MD12031). The high fat
diet (HFD) group was fed a diet containing 60 kcal.% fat, 20 kcal.% protein and 20 kcal.% carbohydrate (Cat.
#MD12033). After 8 weeks of diet intervention, the HFD mice were randomized to 3 groups for another 8 weeks
of treatment as follows: i) HFD alone group (n = 8); ii) HFD +  PF00915275 (11β-HSD1 inhibitor; 5 mg/kg, orally
once every other day) (n = 8); and iii) HFD + C66 (JNK inhibitor; 5 mg/kg, orally once every other day) (n =  8).
Body weight measurements and oral glucose tolerance test (OGTT) were performed at the end of the treatment
period. For OGTT, mice were fasted for 4 h and glucose (2 g/kg body weight) was administrated by oral gavage.
Blood glucose levels were measured with a glucometer at 0, 15, 30, 60 and 120 min after glucose load. At the end
of the study (week 16), the mice were anesthetized using isoflurane anesthesia and sacrificed after 12 h fasting
period. The subcutaneous adipose tissue was harvested for gene and protein expression analysis.

Real-time quantitative PCR.

Cells or tissues were homogenized in TRIZOL (Thermo Fisher) for extraction of RNA. Reverse transcription and quantitative PCR were carried out using a two-step M-MLV Platinum
SYBR Green qPCR SuperMix-UDG kit (Thermo Fisher). Eppendorf Mastercycler ep realplex detection system
(Eppendorf, Hamburg, Germany) was used for q-PCR analysis. Primers were obtained from Thermo Fisher. The
sequences were: AGGAGATGTTGGAATGACAGG (forward) and CTGAACGCTGAGCGATACATA (reverse)
for Adiponectin, CATCAGCGTAAATGGGGATT (forward) and TCGACTTTCCATCCCACTTC (reverse)
for FABP-4, GCCAGCCTACGCCACCATAG (forward) and AGCAGAGCCACGGTCATCAAG (reverse) for
GLUT4, CAACAGCAGCAGCAGTCTTCC (forward) and CCGAGCCAGTCTCTTCTCTAGG (reverse) for
IRS1, and CCGTGAAAAGATGACCCAGA (forward) and TACGACCAGAGGCATACAG (reverse) for β- actin.
The amount of each gene was determined and normalized to the amount of β-actin.

Western immunoblot analysis. Cells or tissues were lysed and 50 μg of lysate were separated by 10%
SDS-PAGE and transferred to PVDF membranes. The membranes were pre-incubated for 1.5 h at room temperature in Tris-buffered saline, pH 7.6, containing 0.1% Tween 20 and 5% non-fat milk. Following primary antibody
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incubation, immunoreactive bands were detected by horseradish peroxidase-conjugated secondary antibodies
and enhanced chemiluminescence reagents (Bio-Rad, Hercules, CA). The intensity of the bands was analyzed
using Image J analysis software version 1.38e (National Institutes of Health, Bethesda, MD) and normalized to
their respective control.

Statistical analysis. The statistical significance of differences was obtained by the student’s t test or ANOVA
with multiple comparisons in GraphPad Pro (GraphPad, San Diego, CA). Differences were considered to be significant at P < 0.05. Data are presented as means ±  SEM.
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